Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
AssigneeProQR Therapeutics, Inc.
InventorsMarko POTMAN, Aliye Seda YILMAZ-ELIS, Aron KOS
Life of this patent
Estimating the term…
Abstract
The disclosure relates to the field of diseases caused by iron overload, such as homeostatic iron regulator protein (HFE) hemochromatosis. The disclosure provides oligonucleotides for RNA editing technology in targeting and deaminating the c.845G>A nucleotide in transcripts of the p.Cys282Tyr (C282Y) mutant human HFE gene to reduce iron overload, especially in the liver.
Claims21
An RNA editing oligonucleotide (EON) capable of forming a double-stranded complex with a region of an endogenous human HFE transcript molecule in a cell, wherein the region of the HFE transcript molecule comprises a target adenosine, and wherein the double-stranded complex can recruit an endogenous ADAR enzyme to deaminate the target adenosine into an inosine, thereby editing the HFE transcript molecule.
Dependencies are inferred from the claim text.